In:
Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 4601-4601
Abstract:
Abstract 4601 Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis. To determine the role of Hyper-CVAD chemotherapy and autologous stem cell transplantation (ASCT) in PTCL, we retrospectively analyzed the outcomes of 31 patients with PTCL between 1999 and 2009. 15 patients received Hyper-CVAD chemotherapy with 3-year overall survival (OS) of 52.4% and 3-year progression free survival (PFS) of 25.7%. 16 patients received ASCT with 3-year OS of 76.2% and 3-year PFS of 61.3%. There was significant difference in 3-year PFS between the two treatments (P=0.012). Additionally, patients underwent ASCT with elevated LDH, ≥ 2 IPI points and extranodal involvement had a favorable outcome comparing with the ones received Hyper-CVAD chemotherapy. These findings might suggest that ASCT likely offer a durable survival benefit for patients with aggressive peripheral T cell lymphoma. Disclosures: No relevant conflicts of interest to declare.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.V116.21.4601.4601
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2010
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Permalink